Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11][12] polycythemia vera, when there has been an inadequate response to or intolerance ...

JAKAVI® (ruxolitinib) for the treatment of myelofibrosis and for the treatment of polycythaemia vera in patients resistant to or intolerant of hydroxyurea.

Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

针对靶点： JAK1/JAK2，Ruxolitinib (INCB018424)是第一个应用于临床的，有效的，选择性JAK1/2抑制剂，在无细胞试验中IC50为3.3 nM/2.8 nM。 作用于JAK1，JAK2与作用于JAK3相比，选择性高130多倍。 生产公司： 诺华 （Novartis）制药. 医保报销适应症/医保报销范围：限中危或高危的原发性骨髓纤维化 (PMF)、真性红细胞增多症继发的骨髓纤维化 (PPV-MF)或原发性血小板增多症继发的骨髓纤维化 (PET-MF)的患者。 医保报销后价格：纳入医保支付前，职工首先 …

Jakavi/Jakafi是一种口服JAK1/2抑制剂，已获批多个治疗适应症。 REACH3临床研究主要终点数据. 2021年07月15日讯 / 生物谷 BIOON/ -- 诺华 （Novartis）与合作伙伴Incyte近日联合宣布，评估口服JAK1/2抑制剂Jakavi/Jakafi（ruxolitinib，鲁索替尼）治疗类固醇难治性慢性移植物抗宿主病 (GvHD)关键3期REACH3研究（NCT03112603）的阳性结果已发表于国际顶级医学期刊《新英格兰医学杂志》（NEJM），文章标题为： Ruxolitinib for Glucocorticoid-Refractory Chronic …

Jakavi is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies

The JAKAVI® (ruxolitinib) mechanism of action in myelofibrosis, including JAK1 and JAK2 inhibition, with binding regardless of JAK2V617F mutation status

Jakavi 的最高劑量為25毫克每日兩次。 如果漏服一劑，患者不可額外多服一劑藥物，而應依據平常的處方劑量服用下一劑藥物。 只要效益風險評估仍維持正面的結果，便可持續治療。

捷可衛錠 5毫克 JAKAVI 5mg tablet 的適應症為 1. 適用於治療中度風險或高風險之骨髓纖維化，包括原發性骨髓纖維化、真性紅血球增多症後骨髓纖維化、或血小板增多症後骨髓纖維化。

Learn more about JAKAVI® (ruxolitinib) for the treatment of polycythaemia vera, including efficacy, safety, dosing, and mechanism of action